drugset / Trial / NCT00592904

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

NCT00592904

Phase 2/3 Completed 262 enrolled Eisai Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and continued efficacy of perampanel in patients previously enrolled in double-blind, placebo-controlled studies for Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN).

Timeline

Start
2008-01
Primary completion
2009-11
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Perampanel Small molecule 12 mg Oral

Indications